Lysine auxotrophy combined with deletion of the secA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Hinchey, Joseph ^a   Jeon, Bo Y ^b   Alley, Holly ^c   Chen, Bing ^a   Goldberg, Michael ^a   Derrick, Steven ^d   Morris, Sheldon ^d   Jacobs Jr , William R ^a   Porcelli, Steven A ^a   Lee, Sunhee ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; LYSINE; PROTEIN SECA; PROTEIN SECA2; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; BACTERIAL PROTEIN; CARRIER PROTEIN; LIVE VACCINE; SECA2 PROTEIN, MYCOBACTERIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUXOTROPHY; BACTERIAL STRAIN; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DRUG EFFICACY; GENE DELETION; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; TREATMENT OUTCOME;

MUS; MYCOBACTERIUM TUBERCULOSIS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOPTOSIS; BACTERIAL PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; GENE DELETION; LYSINE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; TREATMENT OUTCOME; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED;

EID: 79251551969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015857     Document Type: Article

References (32)

1. Maher D, Raviglione M (2005) Global epidemiology of tuberculosis. Clin Chest Med 26: 167-182, v.
2. Kaufmann SH, Hussey G Lambert PH New vaccines for tuberculosis. Lancet 375: 2110-2119.
3. Villarreal-Ramos B (2009) Towards improved understanding of protective mechanisms induced by the BCG vaccine. Expert Rev Vaccines 8: 1531-1534.
4. Andersen P (2007) Tuberculosis vaccines - an update. Nat Rev Microbiol 5: 484-487.
5. Behar SM, Woodworth JS, Wu Y (2007) Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev Vaccines 6: 441-456.
6. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC (2009) Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 21: 331-338.
7. Skeiky YA, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4: 469-476.
8. Andersen P, Doherty TM (2005) The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
9. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, et al. (2007) Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 117: 2279-2288.
10. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacilli Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
11. Consaul SA, Jacobs WR, Jr., Pavelka MS, Jr. (2003) Extragenic suppression of the requirement for diaminopimelate in diaminopimelate auxotrophs of Mycobacterium smegmatis. FEMS Microbiol Lett 225: 131-135.
12. Pavelka MS, Jr., Jacobs WR, Jr. (1996) Biosynthesis of diaminopimelate, the precursor of lysine and a component of peptidoglycan, is an essential function of Mycobacterium smegmatis. J Bacteriol 178: 6496-6507.
13. Winau F, Hegasy G, Kaufmann SH, Schaible UE (2005) No life without death-apoptosis as prerequisite for T cell activation. Apoptosis 10: 707-715.
14. Wherry EJ, Ahmed R (2004) Memory CD8 T-cell differentiation during viral infection. J Virol 78: 5535-5545.
15. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R (2004) Antigenindependent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A 101: 16004-16009.
16. Seder RA, Ahmed R (2003) Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 4: 835-842.
17. Sambandamurthy VK, Jacobs WR, Jr. (2005) Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7: 955-961.
18. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR, Jr. (2003) Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 4: 949-955.
19. Pavelka MS, Jr., Chen B, Kelley CL, Collins FM, Jacobs Jr. WR, Jr. (2003) Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect Immun 71: 4190-4192.
20. Ha SJ, West EE, Araki K, Smith KA, Ahmed R (2008) Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 223: 317-333.
21. Braunstein M, Brown AM, Kurtz S, Jacobs WR, Jr. (2001) Two nonredundant SecA homologues function in mycobacteria. J Bacteriol 183: 6979-6990.
22. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911-4927.
23. Vogel TU, Allen TM, Altman JD, Watkins DI (2001) Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection. J Virol 75: 2458-2461.
24. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, et al. (2002) Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169: 3447-3458.
25. Fuller MJ, Zajac AJ (2003) Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 170: 477-486.
26. Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, et al. (2003) Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37: 1226-1233.
27. Ladel CH, Daugelat S, Kaufmann SH (1995) Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 25: 377-384.
28. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
29. Serbina NV, Flynn JL (2001) CD8 (+) T cells participate in the memory immune response to Mycobacterium tuberculosis. Infect Immun 69: 4320-4328.
30. Bardarov S, Bardarov Jr. S, Jr., Pavelka Jr. MS, Jr., Sambandamurthy V, Larsen M, et al. (2002) Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148: 3007-3017.
31. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456-460.
32. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, et al. (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8: 1171-1174.